CENTRAL SEROUS CHORIORETINOPATHY COMPLICATED BY CHORIOIDAL NEOVASCULARIZATION (CLINICAL CASE)
Abstract
Central serous chorioretinopathy (CSC) is a multifactorial disease characterized by the development of serous desquamation of the neurosensory retina and/or retinal pigment epithelium (RPE) in the macular region, which leads to deterioration of visual functions. This paper presents a clinical case of a patient with long-term recrudescent CSC, complicated by neovascularization. In addition to standard ophthalmological methods, optical coherence tomography (OCT) and optical coherence tomography with angiography (OCT-angiography) were used to examine the patient. After the course of intravitreal administration of anti-VEGF therapy of ranibizumab and aflibercept, positive dynamics was observed.
About the Authors
A. Sh. Zagidullina
ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
R. A. Khisamieva
ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
L. I. Gilemzyanova
ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
M. Yu. Pavlenko
ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
References
1. Азнабаев Б.М. Оптическая когерентная томография + ангиография в диагностике, терапии и хирургии глазных болезней / Б.М. Азнабаев, Т.И. Мухамадеев, Т.И. Дибаев. - М.: Август Борг, 2019. - 352 с
2. Современные представления об этиологии, патогенезе, клинике и лечении центральной серозной хориоретинопатии / А.П. Гойдин [и др.] // Вестник российских университетов. Математика. - 2015. - Т. 20, №4. - C. 784-790
3. Результаты комплексного лечения пациентов с хронической рецидивирующей центральной серозной хориоретинопатией / Н.П. Паштаев [и др.] // Медицинский альманах. - 2016. - Т.41, №1. - С. 105-108
4. Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy / E.K. Chin [et al.] // Clin Ophthalmol. - 2015. - Vol. 9. - 1449-56. 5. Evans, P. Central serous chorioretinopathy (CSCR). Risk factors, diagnosis and management / P. Evans // NY, Eye and Vision Research Developments. - 2017. - P. 130
5. Evans, P. Central serous chorioretinopathy (CSCR). Risk factors, diagnosis and management / P. Evans // NY, Eye and Vision Research Developments. - 2017. - P. 130
6. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy / W.C. Huang [et al.] // Eye (Lond). - 2009. Vol. 2. - P. 488-9
7. Central Serous Chorioretinopathy / T.P. Kean [et al.] // Ophthalmology, 2018. URL: https://emedicine.medscape.com/article/1227025-overview
8. Central serous chorioretinopathy: Current update on pathophysiology and multimodal imaging / G.J. Manayath [et al.] // Oman. J. Ophthalmol. - 2018. - Vol. 11. - P. 103-112
9. Central serous chorioretinopathy: Update on pathophysiology and treatment / B. Nicholson [et al.] // Surv. Ophthalmol. - 2013. - Vol. 58. P. 103-26
10. Salmon, J.F. Kanski's Clinical Ophthalmology. A Systematic Approach. 9th Edition / J.F. Salmon // Elsevier Limited, 2020. - P.381-383
11. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports) / M.E. Torres-Soriano [et al.] // Graefes Arch. Clin. Exp. Ophthalmol. - 2008. - Vol.246, №9. - 1235-9
Review
For citations:
Zagidullina A.Sh., Khisamieva R.A., Gilemzyanova L.I., Pavlenko M.Yu. CENTRAL SEROUS CHORIORETINOPATHY COMPLICATED BY CHORIOIDAL NEOVASCULARIZATION (CLINICAL CASE). Bashkortostan Medical Journal. 2020;15(4):24-27. (In Russ.)
Views:
81
Email this article 
